Seres Therapeutics MCRB delivered earnings and revenue surprises of 20.90 and 196.50 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics, Inc. (MCRB) — Live Session & Technical Brief
Updated Nov 17, 2026 5:04 PM ET · Prev Close $1.41
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.00%) in Biotechnology
Seres Therapeutics, Inc. (MCRB) is trading within a tight intraday band at $1.41 (+0.00%, 0.61x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, MCRB is outperforming the S&P 500 by +1.01%. 14-day RSI stands at 23.8, keeping momentum in a oversold regime.
Seres Therapeutics MCRB delivered earnings and revenue surprises of 20.90 and 196.50 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Price ($1.41) trades relative to 20-day SMA ($1.81) and 50-day SMA ($2.79).
Market & Sector Relative Strength
MCRB outperforming the S&P 500 by +1.01%Recent MCRB Catalyst Headlines
Verified WireMCRB on Wednesday reported a loss of 16.The Cambridge, Massachusetts-based company said it had a loss of 1.
Prevention approach aims to keep patients on immune checkpoint inhibitor ICI therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for Ser-155 Seres expects to subm
Peer-reviewed publication reports a 77 relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with Ser-155 compared with placebo Translational data from the study support t
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.50 (session resistance) for directional breakout confirmation.
Technical Regime (MCRB)
BEARISH MA TRENDRetail & Crowd Sentiment
Very BullishStockTwits messages express bullish anticipation towards $MCRB, mentioning potential partnerships with companies such as $MRK, $BMS.X, $TAK, and $AZN. No recent news articles were available.
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome …
Get Instant MCRB Catalyst Alerts
Receive an email alert when MCRB triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversMCRB Session & Catalyst FAQ
Why is MCRB stock trading near flat today?
Seres Therapeutics, Inc. (MCRB) is trading within a tight intraday band at $1.41 (+0.00%, 0.61x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, MCRB is outperforming the S&P 500 by +1.01%. 14-day RSI stands at 23.8, keeping momentum in a oversold regime.
Is MCRB stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.61x relative volume (low participation). Our multi-factor model currently rates MCRB as HOLD. Review full valuation, quality, and timing signals on the MCRB Buy or Sell Decision Brief →
What is MCRB's intrinsic value and expected trading range?
At $1.41, MCRB's modeled 1-to-3 session range is $1.38 – $1.44, with a key inflection level at $1.50 (session resistance). Compare current price against multi-year cash flow projections in the MCRB Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for MCRB?
RSI at 23.8 indicates oversold conditions — watch for mean-reversion support. MCRB trades at $1.41 relative to its 20-day SMA ($1.81) and 50-day SMA ($2.79), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.